BUZZ-与拉斐尔控股公司达成合并协议后，Cyclo Therapeutics 公司股价下跌

Reuters08-22

((自动化翻译由路透提供，请见免责声明 ))

8月22日 - ** 药物开发商Cyclo Therapeutics 股价盘前下跌23.02%至97美分

** 该公司称已与 Rafael Holdings (link) 签订了合并协议，将两家公司合并。

** 这两家公司将专注于开发 trappsol cyclo，该产品正处于晚期研究阶段，用于治疗一种名为 C1 型尼曼-皮克病的罕见遗传性疾病。

** 48 周中期分析结果预计将于 2025 年中期公布

** 合并完成后，拉斐尔控股将向CYTH股东发行B类普通股，交换比率为CYTH股票估值95美分/股，拉斐尔控股估值为现金价值加上有价证券和其他一些投资的价值减去某些流动负债。

** 交易预计在 2024 年底完成

** 截至上次收盘，CYTH 累计下跌约 21

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461318855?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461318855","market":"us","top_or_hot":-1,"title":"BUZZ-与拉斐尔控股公司达成合并协议后，Cyclo Therapeutics 公司股价下跌","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    8月22日 - ** 药物开发商<a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>   股价盘前下跌23.02%至97美分</p><p>** 该公司称已与 Rafael Holdings    (link) 签订了合并协议，将两家公司合并。 </p><p>** 这两家公司将专注于开发 trappsol cyclo，该产品正处于晚期研究阶段，用于治疗一种名为 C1 型尼曼-皮克病的罕见遗传性疾病。</p><p>** 48 周中期分析结果预计将于 2025 年中期公布</p><p>** 合并完成后，拉斐尔控股将向CYTH股东发行B类普通股，交换比率为CYTH股票估值95美分/股，拉斐尔控股估值为现金价值加上有价证券和其他一些投资的价值减去某些流动负债。</p><p>** 交易预计在 2024 年底完成</p><p>** 截至上次收盘，CYTH 累计下跌约 21 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-与拉斐尔控股公司达成合并协议后，Cyclo Therapeutics 公司股价下跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-与拉斐尔控股公司达成合并协议后，Cyclo Therapeutics 公司股价下跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 19:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    8月22日 - ** 药物开发商Cyclo Therapeutics   股价盘前下跌23.02%至97美分** 该公司称已与 Rafael Holdings    (link) 签订了合并协议，将两家公司合并。 ** 这两家公司将专注于开发 trappsol cyclo，该产品正处于晚期研究阶段，用于治疗一种名为 C1 型尼曼-皮克病的罕见...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RFL","symbol_name":"Rafael Holdings, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2461318855","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461318855","pubTimestamp":1724325938,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    8月22日 - ** 药物开发商Cyclo Therapeutics   股价盘前下跌23.02%至97美分** 该公司称已与 Rafael Holdings     签订了合并协议，将两家公司合并。** 48 周中期分析结果预计将于 2025 年中期公布** 合并完成后，拉斐尔控股将向CYTH股东发行B类普通股，交换比率为CYTH股票估值95美分/股，拉斐尔控股估值为现金价值加上有价证券和其他一些投资的价值减去某些流动负债。** 交易预计在 2024 年底完成** 截至上次收盘，CYTH 累计下跌约 21","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"RFL":"Rafael Holdings, Inc.","LENZ":"Therapeutics","BK4205":"房地产经营公司","BK4139":"生物科技","CYTH":"Cyclo Therapeutics","BK4233":"房地产运营公司","BUZZ":"VanEck Social Sentiment ETF"},"translate_title":"BUZZ-Cyclo Therapeutics Inc. Shares Drop After Merger Deal With Raphael Holdings","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"CYTH":1,"LENZ":1,"RFL":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    8月22日 - ** 药物开发商Cyclo Therapeutics   股价盘前下跌23.02%至97美分** 该公司称已与 Rafael Holdings    (link) 签订了合并协议，将两家公司合并。 ** 这两家公司将专注于开发 trappsol cyclo，该产品正处于晚期研究阶段，用于治疗一种名为 C1 型尼曼-皮克病的罕见遗传性疾病。** 48 周中期分析结果预计将于 2025 年中期公布** 合并完成后，拉斐尔控股将向CYTH股东发行B类普通股，交换比率为CYTH股票估值95美分/股，拉斐尔控股估值为现金价值加上有价证券和其他一些投资的价值减去某些流动负债。** 交易预计在 2024 年底完成** 截至上次收盘，CYTH 累计下跌约 21","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461318855"}